SAB Biotherapeutics (SABS) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 82.9% versus a gain of 23.1%. Over five years, SRZN leads with a -73.5% price change compared with -97.1% for SABS. Surrozen is the larger company by market cap ($336.7 million vs $263.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SABS | SRZN |
|---|---|---|
| Share price | $2.90 | $28.65 |
| Market cap | $263.86M | $336.74M |
| 1-day change | +0.69% | +13.94% |
| YTD return | -22.99% | +11.26% |
| 1-year return | +23.08% | +82.87% |
| 5-year return | -97.15% | -73.48% |
| EPS (TTM) | $-1.29 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.15 | $37.83 |
| 52-week low | $2.10 | $11.39 |
| Distance from 52-week high | -43.69% | -24.27% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +301.38% | +68.94% |
| Average volume | 489.83K | 475.02K |
| Shares outstanding | 90.99M | 11.75M |
| Employees | 86 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed SABS by 59.8 percentage points over the past year.
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
SABS vs SRZN FAQ
Which is bigger, SAB Biotherapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $336.74M compared with $263.86M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, SABS or SRZN?
SRZN returned +82.87% over the past 12 months, compared with +23.08% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are SAB Biotherapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.